Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA)
(WorldNews Japan)

Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA) Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years 59% of infants were able to sit without support for at least 5 seconds No new safety signals were identified In August, the FDA approved Evrysdi for the treatment of SMA in adults and children 2 months and older Basel, 28 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi™ (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy (SMA). The...